Alan Meds vs Velvet Rx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Velvet Rx
Best for cash-pay patients comfortable with a compounded-GLP-1 telehealth model who prioritize three publicly-listed SKUs and bundled shipping over LegitScript / NABP certification, named pharmacy partner, or per-state availability verificationStarting at $139/mo
Side-by-Side Comparison
| Feature | Alan Meds | Velvet Rx |
|---|---|---|
| Overall Score | ✓7.7/10 | 6.6/10 |
| Starting Price | ✓$99/mo | $139/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.3 ★ /5 |
| Features | 5 features | ✓8 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Velvet Rx
Pros
- ✓Publicly-disclosed pricing across 3 SKUs (semaglutide injection $299, tirzepatide injection $359, Oral GLP-1 $349) — uncommon transparency in the compounded telehealth segment
- ✓First-month promo pricing displayed verbatim on home: $139 sema / $199 tirz / $189 oral
- ✓Doctor consult, prescription, 4 weeks of medication, AND free 1-2 day shipping all included in single monthly price (verbatim: 'Same price, every dose. No hidden fees')
- ✓FSA / HSA eligibility claimed verbatim on the home
- ✓Three modalities under one roof: injectable sema, injectable tirz, and an oral GLP-1 option
- ✓No insurance accepted — fully cash-pay model with no membership fee disclosed
Cons
- ✗Oral GLP-1 SKU does NOT name the specific drug (Rybelsus? Foundayo? compounded oral semaglutide? — not disclosed) — material transparency gap given the three are clinically distinct (Rybelsus is T2D-indicated only, Foundayo is FDA-approved for chronic weight management, compounded oral has unsettled regulatory status)
- ✗No LegitScript Certified or NABP .pharmacy seal displayed on home or footer
- ✗No legal entity name disclosed publicly (footer reads only 'Copyright © 2025 VelvetRx')
- ✗No physical address disclosed publicly
- ✗No partner pharmacy named — does NOT disclose which 503A or 503B compounding pharmacy fills prescriptions
- ✗States available NOT enumerated — no state-by-state availability disclosure
- ✗Pricing display has internal inconsistency: hero shows '$299 $139 today' for sema; pricing card adds 'Save $60 instantly on your first month, then $100 off each month' which would imply $239 first / $199 ongoing — different math than the headline $139
- ✗Marketing claims include unverifiable percentages ('92% of patients are on track by month one,' '15% average body weight loss in first 90 days,' '9/10 patients say it's the most effective treatment they've ever tried') with no cited methodology, sample size, or independent audit
- ✗No FDA warning letters found for 'Velvet Rx' or 'VelvetRx' in the FDA warning-letter database as of 2026-05-10 — but this absence is not affirmative evidence of pharmacy quality
Our Verdict
Alan Meds edges out Velvet Rx with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Velvet Rx remains a solid alternative, especially if you're looking for cash-pay patients comfortable with a compounded-GLP-1 telehealth model who prioritize three publicly-listed SKUs and bundled shipping over LegitScript / NABP certification, named pharmacy partner, or per-state availability verification.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.